Multiple Sclerosis
News
FDA Okays Subcutaneous Ocrelizumab for MS
The subcutaneous (SC) injection can be administered by a healthcare professional in approximately 10 minutes and is the first and only twice-a-...
Literature Review
Does MS Protect Against Alzheimer’s Disease?
Understanding how MS may protect patients from Alzheimer’s disease may drive new treatment strategies.
News
EMA Warns of Anaphylactic Reactions to MS Drug
Glatiramer acetate is associated with a risk for anaphylactic reactions, which may occur shortly after administration or even months or years...
Literature Review
COMBAT-MS: Therapy Choice for Relapsing-Remitting MS Has ‘Small’ Impact on Disability Progression, Patient-Reported Outcomes
The decision to start or switch a therapy for relapsing-remitting multiple sclerosis did not significantly impact disability progression, but...
Conference Coverage
Shift Needed in Research, Treatment, Care for Aging MS Population
Independent of disease progression, the impact of aging on MS has been underappreciated in research and in clinical practice.
Conference Coverage
Prospective MS Trial Proves Ocrelizumab Efficacy in Under-Represented Populations
A prospective phase 4 clinical trial that recruited solely Black and Hispanic patients could shed light on divergent treatment outcomes.
Conference Coverage
Pediatric Ocrelizumab Dose Established for MS
Pharmacokinetic and pharmacodynamic data show that adult dose is safe and effective for most children.
Conference Coverage
The Positive Effects of Exercise in MS
Conference Coverage
MS in Men: Unusual, and Unusually Challenging
The clinical course is different in men, but it can be challenging to get them to talk about their symptoms.
Conference Coverage
Investigational MS Med Nearly Eliminates Disease Activity on MRI
Among those initially randomly assigned to receive 1200 mg every 4 weeks, 96% were free of new gadolinium-positive lesions at 48 weeks.